Iovance Biotherapeutics, Inc. (IOVA)
Healthcare
- Fundamental
- 3
- Sentiment
- 3
- Technical
- 2
Do Nothing: IOVA is a bounce-only waterfall decline (technicalScore 2 — price 7.76 below SMA20 10.71, SMA50 11.33, EMA9 8.45 and EMA21 9.91 with ADX14 40 and MACD -1.32); the pullback/oversold limit is countertrend (price < SMA50 with MACD < 0), and no breakout stop qualifies — a buy stop above the nearest settled high (7.92) gives entry 7.95 with structure stop 7.28, only 0.73×ATR of risk versus the 1.0×ATR minimum floor for an 11.9%-ATR name.
Company overview
Iovance Biotherapeutics, Inc. is a biotechnology company focused on developing cancer immunotherapy treatments using a patient's own immune system. The company is conducting several Phase 2 clinical trials, including studies on advanced melanoma and cervical cancer. Iovance collaborates with notable institutions such as M.D. Anderson Cancer Center and Novartis Pharma AG.
Fundamental
fairIovance shows strong liquidity but remains loss-making with high execution risks.
Mixed fundamentals: strong commercial momentum and solid liquidity runway (cash/investments roughly $304M; current ratio around 4.35), but the business still runs large losses and negative free cash flow. Execution risk (manufacturing scale-up, reimbursement/adoption, and potential dilution) remains the dominant fundamental swing factor.
Sentiment
fairSentiment is constructive with recent positive catalysts but lacks a clear forward driver.
Dominant story is post-shock digestion of the 2026-10-29 IOV-LUN-202 clinical-data revision that halved the stock, set against a record Q3 (~$122M revenue, ~60% gross margin, $410-420M FY guidance reaffirmed) that the tape did not reward; the news sentiment delta is determinately negative (+0.20 baseline -> +0.07 scoring, ~-0.13) and retail sentiment is indeterminate on a Reddit service failure. A moderate conflicting-catalyst flag (Hold downgrade vs. Buy/$12 price-target raise; record revenue quarter vs. ~48% drawdown) applies the moderate red-flag cap, and with no forward-dated catalyst inside 30 days and no market-rewarded bullish leg, the evidence supports a weak/forming read rather than a genuinely mixed one.
Technical
weakThe stock is in a strong downtrend with no bullish entry point identified.
IOVA scores 2 of 5: a violent primary downtrend (-48% in eleven sessions from 14.81 to 7.76) with price below SMA20 10.71, SMA50 11.33, EMA9 8.45 and EMA21 9.91, ADX14 40.2 and MACD -1.32/-0.96 below zero — a strong DOWN trend, not a bullish base. Only bounce-grade features exist (RSI14 32.8, Williams %R -96.0, MACD histogram contracting from -0.90 to -0.36, Friday +1.7% off the 7.46 low). No bullish entry exists: the pullback/oversold limit is blocked by the countertrend gate (price < SMA50 with MACD < 0), and the nearest settled breakout stop (entry 7.95 above the 7.92 2026-11-12 high) sits 0.67 = 0.73×ATR above the structure stop 7.28, under the 1.0×ATR minimum-risk floor for an 11.9%-ATR name. Technical score 2 < 3 → Do Nothing.
You’re looking at 2026-11-13 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

